This approach involved gene-editing technology to modify allogeneic T cells to express a second-generation CAR targeting CD123 (comprising CD123 scFv-4-1BB-CD3ζ).297 The TCR αβ was inactivated by targeting the TRAC gene using TALEN® nucleases, which helps to reduce the risk of GvHD. The gene discussed is IL3RA; the disease is graft versus host disease.